Ignite Creation Date:
2024-05-05 @ 5:07 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00390533
Status:
COMPLETED
Last Update Posted:
2016-05-24
First Post:
2006-10-19
Brief Title:
An Eight-week Study to Evaluate the Efficacy and Safety of 2 Doses of Saredutant in Patients With Generalized Anxiety Disorder
Sponsor:
Sanofi
Organization:
Sanofi
Study Overview
Official Title:
An Eight-Week Multicenter Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy Safety and Tolerability of Two Fixed Doses 100 and 30 mg Once Daily of Saredutant in Patients With Generalized Anxiety Disorder
Status:
COMPLETED
Status Verified Date:
2016-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective is to evaluate the efficacy of two fixed doses 100 mg and 30 mg once daily of saredutant compared to placebo in patients with generalized anxiety disorder The secondary objectives are to evaluate the efficacy of saredutant on disability and quality of life in patients with generalized anxiety disorder and to evaluate blood levels of saredutant
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| SR48968 | None | None | None |